Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year High – Time to Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) reached a new 52-week high on Monday . The stock traded as high as $18.33 and last traded at $18.17, with a volume of 469345 shares. The stock had previously closed at $16.88.

Analyst Ratings Changes

Several equities analysts have commented on the company. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Canaccord Genuity Group raised their target price on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Royal Bank Of Canada increased their price target on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Finally, Jefferies Financial Group started coverage on Definium Therapeutics in a research report on Thursday, January 29th. They issued a “buy” rating and a $30.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $35.22.

Definium Therapeutics Trading Down 4.9%

The stock’s fifty day moving average price is $14.01 and its two-hundred day moving average price is $11.91. The company has a market capitalization of $1.68 billion, a PE ratio of -8.35 and a beta of 2.57. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). Sell-side analysts anticipate that Definium Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Insiders Place Their Bets

In other Definium Therapeutics news, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the transaction, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the sale, the insider owned 282,576 shares of the company’s stock, valued at $3,715,874.40. This represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 42,667 shares of company stock valued at $561,071. Insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

A number of large investors have recently added to or reduced their stakes in DFTX. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the last quarter. BIT Capital GmbH bought a new position in Definium Therapeutics in the third quarter valued at about $26,000. CWM LLC boosted its position in Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after purchasing an additional 1,796 shares during the last quarter. Fifth Third Bancorp boosted its position in Definium Therapeutics by 5,593.2% in the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after purchasing an additional 3,300 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new stake in shares of Definium Therapeutics during the 3rd quarter valued at about $46,000. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.